Researchers developed nanoparticles coated with cell membranes that deliver a traditional Chinese herbal formula and successfully prevented smooth muscle cells in arteries from becoming foam cells that trap cholesterol. According to Gram Research analysis, these particles reduced plaque size and lowered cholesterol levels in mice with atherosclerosis by blocking two cellular pathways (KLF4 and NF-κB) that trigger harmful cell transformation. However, this research is still in early laboratory and animal testing stages—human trials have not yet begun.
Researchers created tiny particles coated with cell membranes that deliver a traditional Chinese herbal formula to fight atherosclerosis—a disease where fatty buildup clogs arteries. According to Gram Research analysis, these nanoparticles successfully prevented smooth muscle cells in arteries from turning into foam cells that trap cholesterol. In laboratory and animal tests, the treatment reduced plaque buildup, lowered cholesterol levels, and stabilized existing plaques. While these results are encouraging, the research is still in early stages and hasn’t been tested in humans yet.
Key Statistics
A 2026 laboratory study found that membrane-coated nanoparticles carrying a traditional Chinese herbal formula achieved 59.4% encapsulation efficiency and reduced lipid accumulation in arterial smooth muscle cells exposed to oxidized cholesterol.
In mice with atherosclerosis, the nanoparticle treatment demonstrated significant therapeutic efficacy by reducing plaque size and lowering serum cholesterol levels (TC, TG, and LDL) while stabilizing existing plaques through increased fiber area.
The nanoparticles measured approximately 100 nanometers in size with spherical shape and good dispersion, showing no cytotoxicity to arterial cells at concentrations up to 150 micrograms per milliliter.
The herbal formula’s active component, salvianolic acid B, successfully inhibited foam cell formation in laboratory tests, suggesting the traditional medicine’s active ingredients work through the identified cellular pathways.
The Quick Take
- What they studied: Whether specially designed nanoparticles carrying a traditional Chinese herbal formula could treat atherosclerosis by stopping smooth muscle cells in arteries from becoming foam cells that collect cholesterol.
- Who participated: The study used laboratory cell cultures and mice genetically modified to develop atherosclerosis when fed a high-fat diet. No human participants were involved in this early-stage research.
- Key finding: The nanoparticles successfully prevented smooth muscle cells from transforming into foam cells and reduced plaque size in arteries by working through specific cellular pathways (KLF4 and NF-κB).
- What it means for you: This research suggests a potential new treatment approach for heart disease, but it’s still in laboratory and animal testing stages. Don’t expect this treatment to be available soon—many more studies are needed before human testing can begin.
The Research Details
Researchers created nanoparticles—incredibly tiny particles about 100 nanometers in size (much smaller than a human hair)—and coated them with macrophage cell membranes. They filled these particles with an active ingredient from a traditional Chinese herbal formula called Yiqi Huoxue. The team first tested these particles in laboratory dishes containing smooth muscle cells from arteries. They exposed the cells to oxidized cholesterol (which normally causes them to become foam cells) and measured whether the nanoparticles could stop this transformation. The researchers used multiple testing methods to confirm the particles’ size, shape, and ability to release their herbal contents. They also tested whether the particles were toxic to cells at various concentrations.
This research approach is important because it combines modern nanotechnology with traditional medicine. By coating the nanoparticles with cell membranes, researchers made them better at delivering medicine directly to the right cells in arteries. This targeted delivery system could potentially reduce side effects compared to taking medicine throughout the whole body. The study also identified the specific cellular pathways involved, which helps explain how the treatment works.
This is early-stage research conducted in laboratory cells and animal models only. The study demonstrates good scientific methodology with multiple characterization tests confirming particle properties. However, the lack of human testing means results cannot yet be applied to real patients. The research was published in a peer-reviewed journal, which adds credibility. The use of both cell-based and animal models strengthens the findings, but animal results don’t always translate to humans.
What the Results Show
The nanoparticles were successfully created with ideal properties: spherical shape, approximately 100 nanometers in size, and good stability in solution. The particles showed no toxicity to smooth muscle cells at tested concentrations. Most importantly, the nanoparticles significantly prevented smooth muscle cells from transforming into foam cells when exposed to oxidized cholesterol. Oil Red O staining (a test that colors lipids red) showed that the nanoparticles reduced lipid accumulation in cells by 59.4% encapsulation efficiency and 5.61% drug loading rate. The herbal formula and one of its active components, salvianolic acid B, both demonstrated the ability to inhibit foam cell formation. In animal studies using mice with atherosclerosis, the nanoparticles reduced plaque size, lowered cholesterol levels (TC, TG, and LDL), and stabilized existing plaques by increasing the fiber area around them.
The nanoparticles worked by turning off two specific cellular communication pathways: KLF4 and NF-κB. These pathways normally signal cells to transform into foam cells. By blocking these pathways, the treatment prevented the harmful transformation. The particles also promoted the expression of genes that keep smooth muscle cells healthy (Myh11 and Smtn) while suppressing genes associated with foam cell formation (Myh9, Icam-1, Vcam-1, and others). In the animal model, the treatment increased SM22α and SM-MHC expression, proteins that indicate healthy, stable arterial walls.
This research builds on existing knowledge that smooth muscle cell transformation is a key step in atherosclerosis development. Previous studies identified the KLF4 and NF-κB pathways as important in this process. This study is novel because it combines nanotechnology delivery with traditional herbal medicine to target these pathways. The use of cell membrane coating (biomimetic approach) is a newer technique that helps particles evade immune detection and reach target cells more effectively than previous delivery methods.
This research has significant limitations: it has not been tested in humans, only in laboratory cells and genetically modified mice. The sample size for animal studies was not specified. The study doesn’t compare the nanoparticle treatment to standard atherosclerosis medications, so we don’t know if it’s better or worse than existing treatments. The long-term effects and potential side effects in living organisms remain unknown. The herbal formula contains multiple ingredients, so it’s unclear which components are most important. Additionally, results in mice don’t always translate to humans due to biological differences.
The Bottom Line
This research is too early-stage to make clinical recommendations. Current atherosclerosis treatments (statins, blood pressure medications, lifestyle changes) remain the standard of care. People with heart disease should continue following their doctor’s treatment plans. This nanoparticle approach may eventually become a treatment option, but it requires several more years of research, including human clinical trials, before it could be considered for patient use. Confidence level: Low—this is preliminary research.
This research is most relevant to cardiologists, pharmaceutical researchers, and people with atherosclerosis or high cholesterol who are interested in emerging treatments. People currently managing heart disease should not change their treatment based on this research. Researchers in nanotechnology and traditional medicine integration should find this work particularly interesting.
If this research progresses normally, human clinical trials could begin in 3-5 years. Even with successful trials, regulatory approval and availability would likely take another 5-10 years. Most realistic timeline: 10-15 years before this treatment could potentially be available to patients, if all studies are successful.
Frequently Asked Questions
Can I use this nanoparticle treatment for my atherosclerosis right now?
No, this treatment is not yet available for patients. The research is still in early laboratory and animal testing stages. Human clinical trials have not begun. Continue following your doctor’s current treatment plan with proven medications and lifestyle changes.
How do these nanoparticles work differently than current heart disease medications?
These nanoparticles target specific cellular pathways (KLF4 and NF-κB) that cause smooth muscle cells to become foam cells. They deliver herbal medicine directly to artery cells using a cell membrane coating. Current medications work through different mechanisms, and this approach hasn’t been compared to existing treatments in human studies.
When will this treatment be available for patients with heart disease?
If research progresses successfully, human clinical trials might begin in 3-5 years. Even with successful trials, regulatory approval and availability would likely take another 5-10 years. Most realistic timeline is 10-15 years before potential patient availability.
Is this treatment safe based on the research so far?
Laboratory tests showed the nanoparticles caused no toxicity to cells at tested concentrations. However, safety in living humans remains unknown. Animal studies showed positive results, but animal safety doesn’t guarantee human safety. Extensive human testing would be required before determining actual safety.
What should I do now if I have atherosclerosis?
Continue taking prescribed medications, follow your doctor’s dietary recommendations, exercise regularly (150 minutes weekly), maintain a healthy weight, and attend regular check-ups. Monitor your cholesterol levels quarterly. Discuss any new treatments with your cardiologist before making changes.
Want to Apply This Research?
- Users could track their current cholesterol levels (LDL, HDL, triglycerides) and monitor changes over time as they follow their doctor’s treatment plan. Record quarterly lab results and note any lifestyle changes to identify patterns.
- While this specific treatment isn’t available yet, users can implement proven atherosclerosis prevention strategies: reduce saturated fat intake, increase physical activity to 150 minutes weekly, maintain a healthy weight, and take prescribed medications consistently. The app could send reminders for medication adherence and healthy eating choices.
- Set up quarterly check-ins to review cholesterol lab results with your healthcare provider. Track dietary choices, exercise minutes, and medication adherence. Create alerts for upcoming doctor appointments and lab work. As new treatments emerge, discuss them with your cardiologist during regular visits.
This research describes early-stage laboratory and animal studies that have not been tested in humans. The nanoparticle treatment discussed is not currently available for patient use and should not be considered as a treatment option at this time. People with atherosclerosis or high cholesterol should continue following their doctor’s current treatment recommendations, which may include medications, dietary changes, and exercise. Do not stop or change any prescribed medications based on this research. Always consult with your healthcare provider before making any changes to your treatment plan. This article is for informational purposes only and does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.